E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Sub-macular haemorrhage secondary to wet macular degeneration |
|
E.1.1.1 | Medical condition in easily understood language |
Significant bleeding under the retina that has occurred because of abnormally weak blood vessels that are present in wet age-related macular degeneration |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Eye Diseases [C11] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10064930 |
E.1.2 | Term | Age-related macular degeneration |
E.1.2 | System Organ Class | 10015919 - Eye disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10067791 |
E.1.2 | Term | Wet macular degeneration |
E.1.2 | System Organ Class | 10015919 - Eye disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine if intravitreal tissue plasminogen activator (tPA), gas (C3F8) and ranibizumab promote the resolution of submacular haemorrhage (SMH) due to neovascular (wet) age-related macular degeneration, and improve the visual outcome. The primary outcome measure will be the change in mean ETDRS visual acuity at 3 months following treatment.
[Lay notes: ETDRS visual acuity is vision assessed using a specialized eye chart.Please see the lay summary for the other clinical terms in this section] |
|
E.2.2 | Secondary objectives of the trial |
This study will provide data that will help us design a subsequent definitive trial, assuming the results of treatment are positive. It will also tell us which combination of treatments works best, so that the most appropriate treatment is selected for further study.
We will also look at which clinical outcomes are best to measure, including a range of vision tests, and physical measurements of the size of the blood clot and scarring inside the eye (using photographs of the macula). |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Adults of either sex aged 50 years and older;
- SMH associated with treatment naive or previously treated wet AMD;
- SMH involving the fovea and of sufficient density to obscure RPE detail.
- Able to give informed consent |
|
E.4 | Principal exclusion criteria |
- SMH that is known to have been present for greater than 2 weeks duration, as evidenced by history, pre-trial documentation, or fundus appearance;
- Presence of significant vitreous haemorrhage precluding accurate retinal assessment in the study eye;
- Diabetic maculopathy in the study eye;
- Visually significant cataract in the study eye;
- Amblyopia in the study eye;
- Presence of other ocular disease causing concurrent vision loss in the study eye;
- Advanced glaucoma in the study eye (cup-to-disc ratio greater than 0.8);
- Pregnant and or lactating women;
- Women of childbearing potential including those who are not sterilised or at least one year post menopausal;
- Participation in a clinical trial in the preceding 6 months;
- Documented evidence of a visual acuity less than 25 ETDRS letters at three consecutive visits in the study eye, prior to the onset of submacular haemorrhage;
- Participants who are known to have been ineligible for NICE approved ranibizumab therapy prior to the development of the SMH;
- Current treatment for wet age-related macular degeneration with an intravitreal agent other than ranibizumab, bevacizumab or aflibercept;
- Participants who, in the opinion of the Investigator, would not be willing or able to comply with the study protocol, including posturing requirements.
- Unable to give informed consent |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Mean ETDRS visual acuity at 3 months. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
- Mean ETDRS visual acuity at months 1 and 12
- Percentage of eyes with 15 letters or greater improvement in ETDRS distance
visual acuity at month 12
- Percentage of eyes with 0 letters or greater improvement in ETDRS distance
visual acuity at month 12
- Percentage of eyes with 15 letters or greater loss in ETDRS distance visual
acuity at month 12
- Mean total area of macular haemorrhage on colour fundus photography at
months 1, 3 and 6
- Greatest linear dimension of macular haemorrhage on colour fundus
photography at month 1, 3 and 6
- Presence of subfoveal blood on colour fundus photography at month 1
- Mean central retinal thickness on optical coherence tomography at months 1 and 12
- Mean area of fibrosis on fluorescein angiography at month 12
- Greatest linear dimension of fibrosis on fluorescein angiography at month 12
- LOCSII cataract score at month 12
- Mean Pelli-Robson contrast sensitivity at months 1, 6 and 12
- Mean change in National Eye Institute Visual Function Questionnaire (VFQ25) at months 1, 3, 6 and 12 |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Intravitreal 0.3 mLs 100% perfluoropropane gas |
|
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |